Cipla reports jump in Q1FY24 consolidated PAT to Rs. 995.70 Cr

Cipla has reported total income of Rs. 6465.18 crores during the period ended June 30, 2023

Jubilant Ingrevia consolidated Q1 FY2024 PAT up QoQ at Rs. 57.59 Cr

Jubilant Ingrevia has reported total income of Rs. 1083.52 crores during the period ended June 30, 2023

13.91 crore teleconsultations have been completed:PIB

1. 10 crore teleconsultations have been rendered to senior citizens and 5,22,15,224 to women

Glenmark Life Sciences reports robust 25% EBITDA growth in Q1FY24

The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.

SEBI approves Piramal Pharma’s Rs 1,050-crore rights issue

Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders

Astellas receives FDA priority review for Zolbetuximab biologics license application

Astellas stands on the forefront of healthcare change to turn innovative science into value for patients

Lupin receives tentative approval from USFDA for Dolutegravir Tablets for oral suspension

Dolutegravir Tablets for Oral Suspension (RLD Tivicay PD®) had estimated annual sales of USD 1 million in the U.S. (IQVIA MAT March 2023)

Industry needs to establish a self-regulatory body to maintain the quality of the pharma products, says Dr Mandaviya

Fortis Healthcare to divest its Vadapalani, Chennai Hospital business operations to Kauvery Group of Hospitals

Lupin receives EIR from FDA for its API manufacturing facility in Vizag

The inspection closed with the facility receiving an inspection classification of NAI